First Trust Advisors LP Acquires 112,772 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

First Trust Advisors LP lifted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 46.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 355,103 shares of the company's stock after acquiring an additional 112,772 shares during the period. First Trust Advisors LP owned approximately 0.16% of Hims & Hers Health worth $8,586,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Means Investment CO. Inc. raised its stake in shares of Hims & Hers Health by 23.5% in the 4th quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock valued at $1,210,000 after purchasing an additional 9,508 shares during the period. Principal Financial Group Inc. raised its position in Hims & Hers Health by 102.0% in the 3rd quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock valued at $5,349,000 after buying an additional 146,621 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Hims & Hers Health in the 4th quarter valued at approximately $18,048,000. State of Alaska Department of Revenue acquired a new position in Hims & Hers Health during the 4th quarter worth approximately $2,628,000. Finally, Pacer Advisors Inc. bought a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $374,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on HIMS. Citigroup cut their price objective on shares of Hims & Hers Health from $27.00 to $25.00 and set a "sell" rating on the stock in a research report on Friday, April 25th. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Truist Financial dropped their target price on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a report on Thursday, April 10th. Needham & Company LLC raised their price target on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Finally, TD Cowen lowered Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their price target for the stock from $44.00 to $30.00 in a research report on Tuesday. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $36.92.

Hims & Hers Health Stock Up 13.3 %

Shares of NYSE HIMS traded up $4.82 during mid-day trading on Friday, reaching $40.98. 49,512,288 shares of the company were exchanged, compared to its average volume of 16,740,734. The stock has a market capitalization of $9.10 billion, a P/E ratio of 93.14 and a beta of 1.65. The company's 50-day simple moving average is $32.19 and its 200-day simple moving average is $31.30. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million during the quarter, compared to analysts' expectations of $494.56 million. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Soleil Boughton sold 3,236 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $30.19, for a total value of $97,694.84. Following the completion of the transaction, the insider now owns 159,662 shares of the company's stock, valued at $4,820,195.78. The trade was a 1.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the sale, the chief executive officer now owns 97,687 shares in the company, valued at $5,692,221.49. The trade was a 56.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 666,234 shares of company stock valued at $26,387,645 in the last quarter. Company insiders own 17.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.